These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5240367)

  • 21. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia.
    Paprocki J; Versiani M
    Curr Ther Res Clin Exp; 1977 Jan; 21(1):80-100. PubMed ID: 12922
    [No Abstract]   [Full Text] [Related]  

  • 22. A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia.
    Ota KY; Kurland AA
    J Clin Pharmacol New Drugs; 1973; 13(2):99-110. PubMed ID: 4568299
    [No Abstract]   [Full Text] [Related]  

  • 23. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EEG-brain mapping. A method to optimize therapy in schizophrenics using absolute power and center frequency values.
    Schellenberg R; Schwarz A; Knorr W; Haufe C
    Schizophr Res; 1992 Oct; 8(1):21-9. PubMed ID: 1358183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acutely administered haloperidol-induced pattern changes of regional cerebral blood flow in schizophrenics. Observation from subtraction of brain imaging with single photon emission computed tomography using technetium-99m hexamethyl-propyleneamine oxime.
    Jibiki I; Matsuda H; Yamaguchi N; Kurokawa K; Hisada K
    Neuropsychobiology; 1992; 25(4):182-7. PubMed ID: 1454158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long- and short-term effects of sulpiride on sleep-EEG of man].
    Schneider E; Ziegler B; Maxion H; Badawi M
    Arzneimittelforschung; 1974 Jul; 24(7):990-3. PubMed ID: 4368177
    [No Abstract]   [Full Text] [Related]  

  • 27. [Animal and clinical experiments on the hypnotic effects of nitrazepam].
    Takeshima T; Yamaguchi N; Okabe M; Ando J; Takeuchi O
    No To Shinkei; 1968 Mar; 20(3):209-16. PubMed ID: 4877598
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of haloperidol administration on serum MHPG-SO4 levels in chronic schizophrenics.
    Hoaki Y; Nishikawa T; Ida Y; Kohno Y; Tanaka M
    Kurume Med J; 1981; 28(3):197-200. PubMed ID: 7343757
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study.
    Holden JM; Itil TM; Gannon PJ; Keskiner A
    Curr Ther Res Clin Exp; 1971 May; 13(5):298-310. PubMed ID: 4998393
    [No Abstract]   [Full Text] [Related]  

  • 30. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
    Harvey AT; Flockhart D; Gorski JC; Greenblatt DJ; Burke M; Werder S; Preskorn SH
    J Clin Pharmacol; 2004 Oct; 44(10):1173-84. PubMed ID: 15342619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol.
    Levenson AJ; Burnett GB; Nottingham JD; Sermas CE; Thornby JI
    Curr Ther Res Clin Exp; 1976 Nov; 20(5):695-700. PubMed ID: 825356
    [No Abstract]   [Full Text] [Related]  

  • 32. Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics.
    Tanghe A; Declercq H
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):50-3. PubMed ID: 798191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
    Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
    J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.
    Saletu B; Küfferle B; Anderer P; Grünberger J; Steinberger K
    Eur Neuropsychopharmacol; 1990 Nov; 1(1):27-36. PubMed ID: 1983779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
    Pacquay M; Brasseur F
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment.
    Galderisi S; Mucci A; Di Gregorio MR; Bucci P; Maj M; Kemali D
    Eur Neuropsychopharmacol; 1990 Nov; 1(1):51-4. PubMed ID: 2136214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled trial of haloperidol in chronic schizophrenics.
    ENOCH MD; ROBIN AA
    J Ment Sci; 1960 Oct; 106():1459-67. PubMed ID: 13696946
    [No Abstract]   [Full Text] [Related]  

  • 39. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
    Magliozzi JR; Hollister LE
    J Clin Psychiatry; 1985 Jan; 46(1):20-1. PubMed ID: 3965439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.